
7 Drugs Approved for Primary Care: Q3 2025
Catch up on the 7 FDA drug approvals from Q3 2025 most relevant to primary care, including new treatments for cardiometabolic, infectious, and inflammatory diseases.
The US FDA approved several new medications during the third quarter of 2025 that are likely to impact daily practice in primary care. From novel treatments targeting metabolic and cardiovascular diseases to therapies addressing infectious, inflammatory, and respiratory conditions, these approvals expand the options available for clinicians managing common and complex disorders alike. In the slideshow above, find 7 key FDA approvals from July through September 2025 that primary care physicians should be aware of.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.










































































































































































































































































































